Drugs / RINTODESTRANT
RINTODESTRANT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03455270 | May 2018 → Sep 2022 | breast ductal adenocarcinoma, female breast carcinoma | G1 Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RINTODESTRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4059888 ↗ |
| Known as | G1T48 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03455270 ↗ |
| Known as | GIT-48 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4059888 ↗ |
| Known as | XR5-28 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4059888 ↗ |
| Modality | Small molecule | — CHEMBL4059888 ↗ |
| Route | Oral | “single oral dose of G1T48” NCT03455270 ↗ |